MoonLake Immunotherapeutics annual shares outstanding
2020
2022
2023
2024
2025
MoonLake Immunotherapeutics Shares Outstanding History (MLTX)
MoonLake Immunotherapeutics reported 71.4M shares outstanding at the end of fiscal 2025.
View full MoonLake Immunotherapeutics company overviewMoonLake Immunotherapeutics annual shares outstanding history
| Fiscal year | Period ended | Shares outstanding | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | 71.4M | 8.3M | +13.15% |
| 2024 | 2024-12-31 | 63.1M | 2.6M | +4.32% |
| 2023 | 2023-12-31 | 60.5M | 21.5M | +55.13% |
| 2022 | 2022-12-31 | 39.0M | — | — |
| 2020 | 2020-12-31 | 430,000 | — | — |
MoonLake Immunotherapeutics quarterly shares outstanding
Q4.20
Q3.21
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Shares outstanding | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | 85.1M | 21.6M | +34.08% |
| Q1 2026 | 2026-03-31 | 73.6M | 10.1M | +15.98% |
| Q4 2025 | 2025-12-31 | 71.4M | — | — |
| Q3 2025 | 2025-09-30 | 63.7M | — | — |
| Q2 2025 | 2025-06-30 | 63.5M | — | — |
| Q1 2025 | 2025-03-31 | 63.5M | — | — |
| Q3 2021 | 2021-09-30 | 2.9M | — | — |
| Q4 2020 | 2020-12-31 | 430,000 | — | — |
MoonLake Immunotherapeutics Share Buyback History
A share buyback, also called a stock repurchase, is when a company uses cash to buy its own shares. MoonLake Immunotherapeutics share buyback history shows the reported cash used for repurchases. Buybacks can reduce shares outstanding, but issuance, stock-based compensation, acquisitions, and stock splits can change the share count separately.
MoonLake Immunotherapeutics used $50 to repurchase common stock in fy 2024. Across the latest 3 reported fiscal years, total share repurchases were $50. The latest reported quarter showed $0 of share repurchases.
| Fiscal year | Period ended | Share repurchases |
|---|---|---|
| 2024 | 2024-12-31 | $50 |
| 2023 | 2023-12-31 | $0 |
| 2022 | 2022-12-31 | $0 |
TickerStat uses SEC-reported cash payments for common-stock repurchases. The amounts describe capital returned through buybacks; they are not a forecast or a measure of the number of shares retired.
MoonLake Immunotherapeutics shares outstanding trends
Over the last five fiscal years, MoonLake Immunotherapeutics's shares outstanding moved from 430,000 to 71.4M, a change of 70.9M. The latest reported quarter, Q2 2026, shows 85.1M.
About the metric
What shares outstanding means
Shares outstanding is the number of common shares held by investors at a reporting-period end. The count can change because of stock issuance, repurchases, conversions, acquisitions, or stock splits.
Calculation and source
SEC-reported period-end shares
TickerStat displays period-end common shares from SEC filings and adjusts older values to the current share basis when a stock-split conversion ratio is reported directly or evidenced by a later filing’s restated historical share balance. After repeated reverse splits, an old period can represent less than one current-basis share; this is a split-adjusted equivalent, not a literal historical certificate count. Values remain as reported when no reliable split ratio is available. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review MoonLake Immunotherapeutics source filings ↗